Abstract: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Grant
Filed:
December 8, 2009
Date of Patent:
August 7, 2012
Assignee:
Neurosearch A/S
Inventors:
Dan Peters, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Tino Dyhring Jørgensen, Daniel B Timmermann
Abstract: Potassium channel modulating agents of Formula Ia or Ib and enantiomers and mixtures enantiomers and N-oxides thereof, and pharmaceutically acceptable salts thereof, and their use in the preparation of pharmaceutical compositions. Also, pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, e.g.
Type:
Grant
Filed:
October 3, 2007
Date of Patent:
July 17, 2012
Assignee:
Neurosearch A/S
Inventors:
Birgitte L. Eriksen, Ulrik Svane Sørensen, Charlotte Hougaard, Lene Teuber, Dan Peters, Palle Christophersen, Tina Holm Johansen
Abstract: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the treatment of diabetic patients.
Type:
Grant
Filed:
October 31, 2006
Date of Patent:
June 19, 2012
Assignee:
Neurosearch A/S
Inventors:
Klaus Dugi, Andreas Raschig, Juergen Reess, Frank Berger, Laurence Salin
Abstract: This invention provides 2,3-diamino-quinazolinone compounds of Formula (I) stereoisomers thereof, pharmaceutically-acceptable addition salts thereof, and N-oxides thereof, wherein the variables are as defined in the specification. The 2,3-diamino-quinazolinone compounds have medical utility. The 2,3-diamino-quinazolinone compounds can be used for the manufacture of medicaments, including pharmaceutical compositions. This invention also provides methods of treating disorders, diseases, or conditions which are responsive to activation of Kv7 channels.
Type:
Grant
Filed:
May 22, 2008
Date of Patent:
May 15, 2012
Assignee:
Neurosearch A/S
Inventors:
Carsten Jessen, William Dalby Brown, Joachim Demnitz, Dorte Strøbæk, Mads P. G. Korsgaard, Palle Christophersen
Abstract: The present application discloses novel substituted naphthyridine derivatives of Formula (I) and their use as modulators of the voltage gated Kv7 (KCNQ) potassium ion channels. In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.
Type:
Application
Filed:
April 21, 2010
Publication date:
May 10, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
William Dalby Brown, Carsten Jessen, Cecilia Mattsson, Richard Sott, Dorte Strøbæk
Abstract: This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Grant
Filed:
December 5, 2006
Date of Patent:
May 8, 2012
Assignee:
Neurosearch A/S
Inventors:
Dan Peters, Daniel B. Timmermann, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Tino Dyhring
Abstract: This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Type:
Application
Filed:
March 30, 2010
Publication date:
April 26, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Ulrik Svane Sørensen, Birgitte L. Eriksen, Charlotte Hougaard, Dorte Strøbæk, Palle Christophersen
Abstract: This invention relates to novel tetrazole derivatives of formula (I), which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro- degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Application
Filed:
March 17, 2010
Publication date:
April 19, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Bjarne H. Dahl, Gunnar M. Olsen, Dan Peters, Marianne Lerbech Jensen
Abstract: This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines useful as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. Formula (I).
Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Grant
Filed:
May 29, 2007
Date of Patent:
April 17, 2012
Assignee:
Neurosearch A/S
Inventors:
Dan Peters, Gunnar M. Olsen, Elsebet ØStergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jen Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
Abstract: This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Type:
Application
Filed:
March 30, 2010
Publication date:
April 12, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Ulrik Svane Sørensen, Birgitte L. Eriksen, Charlotte Hougaard, Dorte Strøbaek, Palle Christophersen
Abstract: The present applications discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the applications discloses the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Type:
Application
Filed:
May 6, 2010
Publication date:
April 12, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Dan Peters, Elsebet Østergaard Nielsen, Karin Sandager Nielsen, Gordon Munro
Abstract: This invention relates to novel chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Type:
Grant
Filed:
February 13, 2007
Date of Patent:
April 10, 2012
Assignee:
Neurosearch A/S
Inventors:
Dan Peters, John Paul Redrobe, Elsebet Østergaard Nielsen
Abstract: This invention relates to a novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its use in the manufacture of pharmaceutical compositions. The compound of the invention is found to be a cholinergic ligand at the nicotinic acetylcholine receptors. Due to its pharmacological profile the compound of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Grant
Filed:
May 29, 2007
Date of Patent:
April 3, 2012
Assignee:
Neurosearch A/S
Inventors:
Dan Peters, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Daniel B Timmermann, Steven Charles Loechel
Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.1]octane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Application
Filed:
May 12, 2010
Publication date:
March 22, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Jeppe Kejser Christensen, Tino Dyhring
Abstract: The present invention encompasses novel 1,4-dihydro-3,1-benzoxazin-2-one derivatives, which are surprisingly found to be efficacious in animal models of CNS disorders and, as such, are valuable candidates for the prevention or treatment of CNS (Central Nervous System) diseases or disorders.
Type:
Application
Filed:
March 11, 2010
Publication date:
March 22, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Antonio Nardi, Karin de Linde Troelsen, Helle Kirstein Erichsen
Abstract: The present application discloses novel substituted pyridinyl-methylamine derivatives and their use as modulators of the voltage gated Kv7 (KCNQ) potassium ion channels. In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.
Type:
Application
Filed:
March 11, 2010
Publication date:
March 8, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Carsten Jessen, William Dalby Brown, Dorte Strøbæk
Abstract: This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Grant
Filed:
August 6, 2008
Date of Patent:
February 7, 2012
Assignee:
Neurosearch A/S
Inventors:
Antonio Nardi, Jeppe Kejser Christensen, Dan Peters, Gunnar M. Olsen, Tino Dyhring
Abstract: This invention relates to novel 8-aza-bicyclo[3.2.1]octane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
Type:
Grant
Filed:
November 9, 2006
Date of Patent:
February 7, 2012
Assignee:
Neurosearch A/S
Inventors:
Dan Peters, Birgitte L. Eriksen, Elsebet Ostergaard Nielsen, John Paul Redrobe, Gunnar M. Olsen
Abstract: This invention relates to novel dibenzofuranyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Type:
Application
Filed:
January 25, 2010
Publication date:
February 2, 2012
Applicant:
NEUROSEARCH A/S
Inventors:
Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Jeppe Kejser Christensen, Tino Dyhring